Prostate Cancer | Specialty

A Call for Clinical Research

June 9th 2018

Raoul S. Concepcion, MD, FACS, discusses the importance of research opportunities for residents.

Dr. Halabi Discusses Overall Survival Between African-American and Caucasian Men With mCRPC

June 8th 2018

Susan Halabi, PhD, professor of biostatistics and bioinformatics, School of Medicine, Duke Cancer Institute, discusses overall survival between African-American and Caucasian men with metastatic castration-resistant prostate cancer.

Dr. Maughan Discusses Abiraterone Plus Olaparib in mCRPC

June 7th 2018

Benjamin Maughan, MD, PharmD, instructor, Division of Medical Oncology, Huntsman Cancer Institute, discusses the combination of abiraterone acetate (Zytiga) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer.

Dr. Yu on Comorbidities and Therapy Choice in Prostate Cancer

June 6th 2018

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses how comorbidities factor into treatment choice for patients with castration-sensitive prostate cancer.

Olaparib/Abiraterone Improves PFS in mCRPC

June 6th 2018

Combining olaparib (Lynparza) with abiraterone acetate (Zytiga) reduced the risk of disease progression or death by 35% compared with abiraterone alone in pretreated patients with metastatic castration-resistant prostate cancer.

Dr. Hussain Discusses Findings With PARP Inhibitors in Prostate Cancer

June 5th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses findings with PARP inhibitors in prostate cancer.

Dr. George on Results of Abi Race Trial in Prostate Cancer

June 2nd 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the results of the prospective multicenter Abi Race trial, which compared outcomes of African-American and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (Zytiga) and prednisone.

Black Men May Fare Better Than White Men With Standard mCRPC Therapy

June 2nd 2018

Black men with metastatic castration-resistant prostate cancer may experience greater benefits from chemotherapy and hormone-targeting treatment than their white counterparts.

Dr. Hahn on Patient Selection for Abiraterone Versus Docetaxel in mHSPC

May 31st 2018

Andy Hahn, MD, resident, University of Utah School of Medicine, discusses patient selection for abiraterone acetate (Zytiga) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC).

Dr. Choyke on the Importance of Multidisciplinary Care in Prostate Cancer

May 30th 2018

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute (NCI), discusses the importance of multidisciplinary care in prostate cancer.

ASCO 2018: Top Oncologists Select Key, Practice-Changing Abstracts

May 30th 2018

Key opinion leaders spoke with OncLive ahead of the 2018 ASCO Annual Meeting to share the top abstracts they believe could have the greatest impact on clinical practice and patient outcomes across lymphomas, gastrointestinal cancers, genitourinary cancers, and lung cancer.

Dr. Godwin on Immunotherapy Efforts in Prostate Cancer

May 24th 2018

James L. Godwin, MD, physician, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses immunotherapy efforts in prostate cancer.

FDA Approves New Abiraterone Acetate Formulation for mCRPC

May 24th 2018

The FDA has approved a new formulation of abiraterone acetate in combination with methylprednisolone as a treatment for men with metastatic castration-resistant prostate cancer.

Dr. Trabulsi Discusses Postoperative Radiation in Prostate Cancer

May 23rd 2018

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses postoperative radiation in patients with prostate cancer.

Apalutamide Reduces Risk of PSA Progression by 94% in Nonmetastatic CRPC

May 21st 2018

Apalutamide (Erleada) lowered the risk of PSA progression by 94% in patients with nonmetastatic castration-resistant prostate cancer, according to a posthoc analysis from the phase III SPARTAN trial.

ADT and Cardiovascular Risk in Prostate Cancer: Q&A

May 21st 2018

Strategies for Preventing CV Events in Prostate Cancer

May 21st 2018

Managing Metabolic Aberrations and CV Events from ADT

May 21st 2018

Predicting Risk for Metabolic Aberrations and CV Events

May 21st 2018

Metabolic Aberrations Associated With ADT

May 21st 2018